Loading patent…
AssigneeZymoGenetics, Inc.
InventorsKatherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
Estimating the term…
The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
A method of treating an inflammatory disease in a human patient comprising subcutaneously or intravenously administering to the patient a therapeutically effective amount of a bispecific antibody comprising a cross-reactive IL-17A and IL-17F binding entity and an IL-23p19 binding entity, wherein the cross-reactive IL-17A and IL-17F binding entity comprises a humanized antibody derived from the antibody produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-7988, wherein the IL-23p19 binding entity comprises an antibody which specifically binds to the p19 subunit of IL-23, and wherein the inflammatory disease is psoriasis or psoriatic arthritis.
A method of treating an inflammatory disease in a human patient comprising subcutaneously or intravenously administering to the patient a therapeutically effective amount of a composition comprising a bispecific antibody and a pharmaceutically acceptable carrier or diluent, wherein the bispecific antibody comprises a cross-reactive IL-17A and IL-17F binding entity and an IL-23p19 binding entity, wherein the cross-reactive IL-17A and IL-17F binding entity comprises a humanized antibody derived from the antibody produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-7988, wherein the IL-23p19 binding entity comprises an antibody which specifically binds to the p19 subunit of IL-23, and wherein the inflammatory disease is psoriasis or psoriatic arthritis.
Dependencies are inferred from the claim text.